



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



6042 Cornerstone Court W, Ste B  
San Diego, CA 92121  
**Tel:** 1.858.202.1401  
**Fax:** 1.858.481.8694  
**Email:** [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

## Data Sheet

### **LILRB4 NFAT-Luciferase Reporter Jurkat Recombinant Cell Line Catalog #79750**

#### **Product Description**

Recombinant Jurkat cells constitutively expressing human LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4, GenBank Accession #NM\_001278426) and the firefly luciferase gene under the control of NFAT response elements.

#### **Background**

Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4 (LILRB4) contains multiple Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs). LILRB4 expression on Acute Myeloid Leukemia (AML) cells promotes tumor cell infiltration and suppresses T cell activity. Because LILRB4 is highly expressed on AML cells but not on normal hematopoietic stem cells, LILRB4 has been identified as a promising therapeutic target for CAR-T cells.

#### **Applications**

- Screen for novel ligands of LILRB4

#### **Format**

Each vial contains  $\sim 2 \times 10^6$  cells in 1 ml of FBS with 10% DMSO.

#### **Storage**

Immediately upon receipt, store in liquid nitrogen.

#### **Culture conditions**

**Thaw Medium 2 (BPS Bioscience, #60184):** RPMI1640 medium (Life Technologies, #A10491-01) supplemented with 10% FBS (Life Technologies, #26140-079) and 1% Penicillin/Streptomycin (Hyclone, #SV30010.01).

**Growth Medium 2F (BPS Bioscience, #79669):** Thaw Medium 2 (BPS Bioscience, #60184) plus 1 mg/ml of Geneticin (Thermo Fisher, #11811031), 0.5  $\mu$ g/ml Puromycin Dihydrochloride (Thermo Fisher, #A1113803) to ensure recombinant expression.

Cells should be grown at 37°C with 5% CO<sub>2</sub> using Growth Medium 2F to ensure recombinant expression is maintained.

It is recommended to quickly thaw the frozen cells from liquid nitrogen in a 37°C water-bath, and then transfer the entire contents of the vial to a tube containing 10 ml of Thaw Medium 2 **without Geneticin or Puromycin**. Then spin the cells down, remove the supernatant, and resuspend the cells in 5 ml of pre-warmed Thaw Medium 2 **without Geneticin or Puromycin**.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)

Transfer the resuspended cells to a T25 flask and incubate at 37°C in a 5% CO<sub>2</sub> incubator. After 24 hours of culture, add an additional 3-4 ml of Thaw Medium 2 **without Geneticin or Puromycin**. At first passage, switch to Growth Medium 2F **containing Geneticin and Puromycin**. Cells should be split before they reach 2 x 10<sup>6</sup> cells/ml.


### Functional Validation and Assay Performance

Expression of human LILRB4 in the NFAT-Luciferase Jurkat cells was confirmed by FACS.

The functionality of the cell line was validated using an anti-CD3 Agonist Antibody (BPS Bioscience, #71274), and compared with the parental NFAT-Luciferase Jurkat cells (BPS Bioscience, #60621). Treatment with the anti-CD3 Agonist Antibody induces NFAT Luciferase activity, which is partially inhibited by LILRB4 expression.

### Figure 1. FACS analysis of LILRB4 NFAT-Luciferase Jurkat cells.

FACS analysis was performed using a PE anti-human LILRB4 antibody from BioLegend (#333008). Parental NFAT-Luciferase Jurkat cells are shown in green, and LILRB4 NFAT-Luciferase Jurkat cells are shown in blue.




OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)

**Figure 2. Stimulation of NFAT-Luciferase activity with soluble anti-CD3 Agonist Antibody.** Parental NFAT-Luciferase Jurkat cells or LILRB4 NFAT-Luciferase Jurkat cells were plated in triplicate at 15,000 cells/well into a clear-bottom 96-well plate. Cells were then incubated with either 0 or 10 µg/ml anti-CD3 Agonist Antibody for 5 hours at 37°C. After incubation, ONE-Step Luciferase reagent (BPS Bioscience, #60690) was added to the cells to measure NFAT activity.



#### Materials Required for Cell Culture

- Thaw Medium 2 (BPS Bioscience #60184)
- Growth Medium 2F (BPS Bioscience #79669)

#### Materials Required for Cellular Assay

- Assay Medium (Thaw Medium 2 (BPS Bioscience, #60184))
- Thaw Medium 3 (BPS Bioscience, #60186):
  - Ham's F-12 medium (Hyclone # SH30526.01) supplemented with 10% FBS (Thermo Fisher, Cat. #26140079), 1% Penicillin/Streptomycin (Hyclone SV30010.01).
- TCR activator CHO cells (BPS Bioscience, #60539)
- Anti-CD3 Agonist Antibody (BPS Bioscience, #71274)
- NFAT-Luciferase Jurkat Recombinant Cell Line (BPS Bioscience, #60621)
- ANGPTL3 (BPS Bioscience, #91009)
- ANGPTL7 (RND Systems, #914-AN-025)
- 96-well tissue culture-treated white clear-bottom assay plate

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)



6042 Cornerstone Court W, Ste B  
San Diego, CA 92121  
**Tel:** 1.858.202.1401  
**Fax:** 1.858.481.8694  
**Email:** [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

- One-Step luciferase assay system (BPS Bioscience, #60690) or other luciferase reagents for measuring firefly luciferase activity
- Luminometer

### Assay Protocol for Testing Soluble Ligands

1. Harvest TCR activator CHO cells (BPS Bioscience, #60539) from culture and seed cells at a density of 15,000 cells per well into a white clear-bottom 96-well microplate in 100  $\mu$ l of Thaw Medium 3. Leave a couple of wells empty for use as a cell-free control. Incubate the cells at 37°C in a CO<sub>2</sub> incubator overnight.
2. The next day, harvest the LILRB4 NFAT-Luciferase Jurkat cells by centrifugation and resuspend in Assay Medium (Thaw Medium 2, **no Geneticin or Puromycin**). Dilute the cells to 6 x 10<sup>5</sup> cells/ml in the Assay Medium.

Prepare dilutions of the Test Ligand (e.g. ANGPTL3 or ANGPTL7; 25  $\mu$ g/ml) in 25  $\mu$ l of the Assay Medium, and mix with 25  $\mu$ l of the LILRB4 NFAT-Luciferase Jurkat cells. Incubate the Test Ligand with the LILRB4 NFAT-Luciferase Jurkat cells for 30 minutes at room temperature. After incubation, remove the Thaw Medium 3 from the TCR activator CHO cells and add 50  $\mu$ l of the LILRB4 NFAT-Luciferase Jurkat cells / Ligand mixture to the TCR activator CHO cells.

The final cell density of the LILRB4 NFAT-Luciferase Jurkat cells is 15,000 cells per well. Set up each treatment in at least triplicate. Add 50  $\mu$ l of Assay Medium to cell-free control wells (for determining background luminescence).

Incubate the plates at 37°C in a CO<sub>2</sub> incubator for 24 hours.

3. The next day, after a 24-hour incubation, measure the luciferase activity using the ONE-Step Luciferase Assay System: Prepare the ONE-Step reagent as recommended in the protocol. Add 50  $\mu$ l of ONE-Step Luciferase Reagent per well and rock gently at room temperature for ~15 minutes. Measure the luminescence using a luminometer.  
*If using luciferase reagents from other vendors, follow the manufacturer's assay protocol.*
4. Data Analysis: Subtract the average background luminescence (of the cell-free control wells) from the luminescence reading of all wells.

The fold induction of NFAT luciferase reporter expression = background-subtracted luminescence of treated well / average background-subtracted luminescence of untreated control wells.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.


To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)

**Figure 3. Inhibition of LILRB4 NFAT-Luciferase activity using soluble ligands.**

TCR activator CHO cells were seeded in a 96-well plate. The next day, NFAT-Luciferase Jurkat cells or LILRB4 NFAT-Luciferase Jurkat cells were pre-incubated with either ANGPTL3 (BPS Bioscience, #91009) or ANGPTL7 (RND Systems, #914-AN-025) for 30 minutes, and then the Jurkat cells / ligand mixture were added to the TCR activator CHO cells and incubated for 24 hours. After incubation, ONE-Step Luciferase reagent (BPS Bioscience, #60690) was added to the cells to measure NFAT-Luciferase activity.



**Sequence**

Human LILRB4 sequence (accession number NM\_001278426):

```

MIPTFTALLCLGLSLGPRTHMQAGPLPKPTLWAEPGSVISWGN SVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEP
KNKARFSIPSMTE DYAGRYRCYRSPV GWSQPSDPLELVMTGAYSKPTLSALPSPLVTS GKSVTLLCQSRSPMDTFL
LIKERAAHPLLHLRSEHGAQQHQAEFPMSPVTSVHGGTYRCFSSHGF SHYLLSHPSDPLELIVSGSLEGPRPSPTRS
VSTAAGPEDQPLMPTG SVPHSGLRRHWEVLIGVLVVSILL LLLLFLLLQHW RQGKHRTLAQRQADFQRPPGAAEPE
PKDGG LQRRSSPAADVQGENFCAAVKNTQPEDGVEMDTRQSPHDED PQA VTYAKVKHSRPRREMASPPSPLSGEFLD
TKDRQA EEDRQMDTEAAASEAPQDV TYARLHSFTLRQKATEPPPSQEGASPAEPSVYATLAIH
  
```

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)



6042 Cornerstone Court W, Ste B  
San Diego, CA 92121  
**Tel:** 1.858.202.1401  
**Fax:** 1.858.481.8694  
**Email:** [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

#### References:

1. LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration. Deng M, *et al. Nature*. 2018. **562(7728)**:605-609.
2. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. John S, *et al. Mol Ther*. 2018. **26(10)**:2487-2495.

#### License Disclosure

Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [sales@bpsbioscience.com](mailto:sales@bpsbioscience.com) for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.

#### Related Products

<u>Product</u>	<u>Cat. #</u>	<u>Size</u>
LILRA1, Avi-His Tag	100245	100 µg
LILRB2, Avi-His Tag	100234	100 µg
LILRB4, Avi-His Tag	100236	100 µg
LILRB1, Fc fusion, Biotin-labeled	79474	100 µg
LILRB1, Fc fusion	79473	100 µg
Thaw Medium 2	60184	100 ml
Growth Medium 2F	79669	500 ml
Thaw Medium 3	60186	100 ml
TCR activator CHO cells	60539	2 vials
Anti-CD3 Agonist Antibody	71274-1	50 µg
Anti-CD3 Agonist Antibody	71274-2	100 µg
NFAT-Luciferase Jurkat Cell Line	60621	2 vials
ANGPTL3	91009-1	10 µg
ANGPTL3	91009-2	50 µg
ANGPT1	91002	50 µg
ANGPT2	91003	50 µg

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)

Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)